TCL Archive “Critical Issues” Include How U.S. NCI Spends Its Money. “Catastrophic” Cutback In Canada May 14, 1976
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
